COVID-19: Nasal irrigation twice daily immediately after positive test reduces disease – death

1
64

Starting twice daily flushing of the mucus-lined nasal cavity with a mild saline solution soon after testing positive for COVID-19 can significantly reduce hospitalization and death, investigators report.

They say the technique that can be used at home by mixing a half teaspoon each of salt and baking soda in a cup of boiled or distilled water then putting it into a sinus rinse bottle is a safe, effective and inexpensive way to reduce the risk of severe illness and death from coronavirus infection that could have a vital public health impact.

“What we say in the emergency room and surgery is the solution to pollution is dilution,” says Dr. Amy Baxter, emergency medicine physician at the Medical College of Georgia at Augusta University and corresponding author of the study in Ear, Nose & Throat Journal.

“By giving extra hydration to your sinuses, it makes them function better.

If you have a contaminant, the more you flush it out, the better you are able to get rid of dirt, viruses and anything else,” says Baxter.

“We found an 8.5-fold reduction in hospitalizations and no fatalities compared to our controls,” says senior author Dr. Richard Schwartz, chair of the MCG Department of Emergency Medicine. “Both of those are pretty significant endpoints.”

The study appears to be the largest, prospective clinical trial of its kind and the older, high-risk population they studied—many of whom had preexisting conditions like obesity and hypertension—may benefit most from the easy, inexpensive practice, the investigators say.

They found that less than 1.3% of the 79 study subjects age 55 and older who enrolled within 24-hours of testing positive for COVID-19 between Sept. 24 and Dec. 21, 2020, experienced hospitalization. No one died.

Among the participants, who were treated at MCG and the AU Health System and followed for 28 days, one participant was admitted to the hospital and another went to the emergency room but was not admitted.

By comparison, 9.47% of patients were hospitalized and 1.5% died in a group with similar demographics reported by the Centers for Disease Control and Prevention during the same timeframe, which began about nine months after SARS-CoV-2 first surfaced in the United States.

“The reduction from 11% to 1.3% as of November 2021 would have corresponded in absolute terms to over 1 million fewer older Americans requiring admission,” they write. “If confirmed in other studies, the potential reduction in morbidity and mortality worldwide could be profound.”

Schwartz says Baxter brought him the idea early in the pandemic and he liked that it was inexpensive, easy to use and could potentially impact millions at a time where, like other health care facilities, the Emergency Department of the AU Health System was starting to see a lot of SARS-CoV-2-positive patients.

“We were really looking at what options we had available for treatment,” Schwartz says. The first COVID-19 vaccines were given in December 2020 and the first treatment, the antiviral remdesivir was approved by the Food and Drug Administration in October 2020.

They knew that the more virus that was present in your body, the worse the impact, Baxter says. “One of our thoughts was: If we can rinse out some of the virus within 24 hours of them testing positive, then maybe we can lower the severity of that whole trajectory,” she says, including reducing the likelihood the virus could get into the lungs, where it was doing permanent, often lethal damage to many.

Additionally, the now-infamous spiky SARS-CoV-2 is known to attach to the ACE2 receptor, which is pervasive throughout the body and in abundance in locations like the nasal cavity, mouth and lungs. Drugs that interfere with the virus’ ability to attach to ACE2 have been pursued, and Baxter says the nasal irrigation with saline helps decrease the usual robust attachment. Saline appears to inhibit the virus’ ability to essentially make two cuts in itself, called furin cleavage, so it can better fit into an ACE2 receptor once it spots one.

Participants self-administered nasal irrigation using either povidone-iodine, that brown antiseptic that gets painted on your body before surgery, or sodium bicarbonate, or baking soda, which is often used as a cleanser, mixed with water that had the same salt concentration normally found in the body.

While the investigators found the additives really added no value, previous research had indicated they might help, for example, make it more difficult for the virus to attach to the ACE2 receptor. But their experience indicates the saline solution alone sufficed. “It’s really just the rinsing and the quantity that matter,” Baxter says.

The investigators also wanted to know any impact on symptom severity, like chills and loss of taste and smell. Twenty-three of the 29 participants who consistently irrigated twice daily had zero or one symptom at the end of two weeks compared to 14 of the 33 who were less diligent.

Those who completed nasal irrigation twice daily reported quicker resolution of symptoms regardless of which of two common antiseptics they were adding to the saline water.

Sixty-two of the participants completed a daily survey, reporting 1.8 irrigations daily; 11 reported irrigation-related complaints and four discontinued use.

Study participants and those used as controls had similar ages and rates of common conditions including one or more preexisting health problems.

Older adults, those with obesity and excess weight, who are physically inactive and those with underlying medical conditions are considered most at risk for serious complications and hospitalization from COVID-19. A body mass index, or BMI, which measures weight in relation to height, between 18.5 and 24.9, is considered ideal, and study participants had a mean BMI of 30.3; over 30 indicates obesity.

Others have shown the nasal irrigation, also called lavage, can also be effective in reducing duration and severity of infection by a family of viruses that include the coronaviruses, which are also known to cause the common cold, as well as the influenza viruses, the investigators write. “SARS-CoV-2 infection was another perfect situation for it,” Baxter says.

In fact, nasal irrigation is something that has been done for millennia in Southeast Asia, and Baxter had noted lower death rates from COVID-19 in countries like Laos, Vietnam and Thailand. “Those were places that I knew from having been there where they use nasal irrigation as a normal part of hygiene just like brushing their teeth,” she says. A 2019 pre-COVID study provided evidence that regular nasal irrigation in Thailand can improve nasal congestion, decrease postnasal drip, improve sinus pain or headache, improve taste and smell and improve sleep quality.

Schwartz said the simplicity and safety of the treatment had him recommending nasal irrigation to positive patients early on and the published results make him even more confident in recommending nasal irrigation to essentially anyone who tests positive.

Baxter noted the skepticism of the medical community before the results could be peer reviewed and published and her frustration with this relatively simple approach not being used when so many were sick and dying.

“Many of the people who have been using this now for months have told me their seasonal allergies have gone away, that it really makes a huge difference in any of the things that go through the nose that are annoying.”

A study released in September 2020 indicated that gargling with a saline-based solution can reduce viral load in COVID-19, and another released in 2021 suggested that saline works multiple ways to reduce cold symptoms related to infection with other coronaviruses and might work as well as a first-line intervention for COVID-19.

Despite the two nostrils, the nasal sinus is just one cavity, so the water is pushed into one side and comes out the other, Baxter notes.


Importance SARS-CoV-2 enters the nasopharynx to replicate; nasal irrigation soon after diagnosis could reduce viral load and inhibit furin cleavage necessary for cell entry, thereby reducing morbidity and mortality.

Objective To determine whether initiating nasal irrigation after COVID-19 diagnosis reduces hospitalizations and death in high-risk outpatients, and whether irrigant composition impacts severity.

Design Unblinded randomized clinical trial of two nasal irrigation protocols in older outpatients PCR positive for SARS-CoV-2, with an observational arm using laboratory-confirmed cases in the CDC COVID-19 Case Surveillance dataset.

Setting Single-lab community testing facility associated with the emergency department (ED) in Augusta, GA.

Participants A consecutive sample of high-risk adults were enrolled within 24 hours of a positive COVID-19 test between September 24 and December 21 of 2020. Patients aged 55 and older were remotely consented. Among 826 screened, 321 of 694 eligible patients were unable to be reached, 294 refused participation, and 79 participants were enrolled.

Interventions Participants were randomly assigned adding 2.5 mL povidone-iodine 10% or 2.5 mL sodium bicarbonate to 240 mL of isotonic nasal irrigation twice daily for 14 days.

Main Outcomes and Measures The primary outcome was hospitalization or death from COVID-19 within 28 days of enrollment by daily self-report confirmed with phone calls and hospital records, compared to the CDC Surveillance Dataset covering the same time. Secondary outcomes compared symptom resolution by irrigant additive.

Results Seventy-nine high-risk participants were enrolled (mean [SD] age, 64 [8] years; 36 [46%] women; 71% Non-Hispanic White), with mean BMI 30.3. Analyzed by intention-to-treat, by day 28, COVID-19 symptoms resulted in one ED visit and no hospitalizations in 42 irrigating with alkalinization, one hospitalization of 37 in the povidone-iodine group, (1.27%) and no deaths. Of nearly three million CDC cases, 9.47% were known to be hospitalized, with an additional 1.5% mortality in those without hospitalization data. The total risk of hospitalization or death (11%) was 8.57 times that of enrolled patients (SE=2.74; P=.006). 62 completed daily surveys (78%), averaging 1.8 irrigations/day. Eleven had irrigation complaints, and four discontinued. There were no significant differences by additive.

Conclusion SARS-CoV-2+ participants initiating nasal irrigation were over 8 times less likely to be hospitalized than the national rate.

Trial Registration ClinicalTrial.gov Identifier: NCT04559035

Author Approval All authors have filled out ICMJE and approved submission.

Conflict of Interest Statement Materials were provided by Neilmed Inc. and Rhinosystems Inc. The study was supported by funding from the Bernard and Anne Gray Donor Advised Fund Community Foundation for Greater Atlanta, Neilmed Inc., and Rhinosystems. No authors have conflict of interest.

Question After testing positive for COVID-19, will rapidly initiating nasal irrigation reduce the risk of morbidity and mortality compared to a national dataset?

Findings A consecutive sample of 79 high-risk adults (mean age 64, BMI 30.3) were randomized to initiate one of two nasal irrigation protocols within 24 hours of a positive COVID-19 test. Compared to a CDC COVID-19 National Dataset observational arm, 1.27% of participants initiating twice daily nasal irrigation were hospitalized or died, compared to 11%, a significant difference.

Meaning In high-risk outpatients testing positive for SARS-CoV-2 who initiated nasal irrigation rapidly after diagnosis, risk of hospitalization or death was eight times lower than national rates reported by the CDC.

Discussion
Our results support that pressurized nasal irrigation reduces the likelihood of hospitalization in high-risk COVID-19 + patients, suggesting a safe and over the counter measure with potentially vital public health impact. Nationally, the reduction from 11% to 1.3% as of November 2021 would have corresponded in absolute terms to over 1,000,000 fewer older patients requiring admission. While one study found 47% of those 50 and older had continued symptoms 14 – 21 days after diagnoses,16,17 only 13% in our study had symptoms at day 14. If confirmed in other studies, the potential reduction in morbidity and mortality worldwide could be profound.

Clinically COVID-19 differs notably from previous Coronaviridae: children are less impacted; obesity, diabetes, African American race and hypertension are independent risk factors; the relatively pathognomonic symptom of anosmia is present in up to 80% of patients,18,19 and the duration from infection to severe symptoms is prolonged.

The clinical differences in presentation reflect SARS-CoV-2’s primarily nasal entry and nasopharyngeal replication. Olfactory neuroepithelium ACE2 is expressed at 700 times the expression in lungs.19,20 Conditions increasing nasal ACE2 expression (obesity, hypertension, pollution) or sinus size (age, male sex) correlate with increased severity, further supporting targeting viral fusion in the nasopharynx.21-25 In contrast, populations lacking fully developed sinus area (children), with a high baseline practice of nasal irrigation (Laos, Vietnam), or higher mask compliance have decreased severity.26,27 Together, the nasal cavity size, ACE2 expression and variolation explanation could account for lower pediatric severity and spread.28 The degree of methylation of the ACE2 receptors (and thus stiffness and ease of viral attachment) is related to both race and epigenetic stress.29,30 Thus, increased virulence correlating with increased area, quantity and stability of the spike proteins supports the mechanical target hypothesis. Given the local cell-to-cell rather than hematogenous spread and delay in activation of lung TMPRRS2,31 mechanically debriding viral particles lodged in the ACE2 receptor, but not yet fused, could reduce severity. Furthermore, the variation in severity with methylation implies that not all particles become securely attached. The size variations in the entire nasal cavity, rather than just anterior nares, support the concept that full nasal cavity irrigation may be superior to nasal spray. Finally, the number of asymptomatic cases and the correlation of illness severity with viral load implied that even after PCR positivity, a window exists wherein lowering the viral load through irrigation could be clinically advantageous.

Ignaz Semmelweis pioneered handwashing to remove bacteria in 1847. In emergency medicine and surgery, debriding infectious material with copious high-powered irrigation is standard practice. While nasal irrigation reduced symptoms of other Coronaviridae, flu,4 and bacterial carriage in otolaryngology32,33, pathology from local spread and aspiration and the continued production of viral load locally suggest a potentially greater impact on COVID-19. Association of viral load with severity 27,34,35 suggests a different kind of cumulative pathology related to immune response, as well as the potential for reducing severity after the fact by debridement. Multiple studies have demonstrated immediate viral load reductions in vitro and in vivo with direct oral or nasal application of antivirals,8-10 or the theoretical benefit of lavaging and gargling.36-38 One study of povidone-iodine gargles and sprays in 24 patients did not show a significant reduction in viral load, but the age difference of 23 years between control and intervention groups calls randomization into question.39 An interim analysis of a twice daily nasal irrigation trial in 45 young adults showed initial clinical improvement,17 but was ultimately underpowered.

To our knowledge this is the largest prospective clinical trial using both twice daily large volume irrigation with a virucidal arm, and with documented adherence to irrigation. Moreover, the older and higher risk population in this study may be most relevant to reducing morbidity and mortality.

reference : https://www.medrxiv.org/content/10.1101/2021.08.16.21262044v3.full-text


More information: Amy L Baxter et al, Rapid initiation of nasal saline irrigation to reduce severity in high-risk COVID+ outpatients, Ear, Nose & Throat Journal (2022). DOI: 10.1177/01455613221123737

1 COMMENT

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Questo sito usa Akismet per ridurre lo spam. Scopri come i tuoi dati vengono elaborati.